Education
About Us
Working with TipRanks
Follow Us
Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
Earnings Data
Report Date
Mar 09, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.21Last Year’s EPS
-0.63Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with strong revenue growth, increased prescriptions, and positive clinical data. The raised revenue guidance and inclusion in NCCN guidelines further support a positive trajectory. However, the high gross-to-net ratio and limited impact of EAP patients were noted challenges.Company Guidance
Quarterly Revenue Growth
Day One Biopharmaceuticals reported $38.5 million in net product revenue for Q3 2025, marking a 15% quarter-over-quarter increase, the strongest so far in 2025.
Steady Prescription Growth
Total prescriptions grew by 18% with over 1,200 total prescriptions. New patient starts accelerated by almost 20% quarter-over-quarter.
Raised Revenue Guidance
The company raised its full-year revenue guidance to a range of $145 million to $150 million for 2025, reflecting confidence in the growth trajectory of OJEMDA.
Positive Clinical Data
The 2-year FIREFLY-1 data included in the OJEMDA label demonstrate a manageable safety profile and durable clinical benefit, with median duration of response increasing from 13 to 18 months.
NCCN Guideline Inclusion
Tovorafenib was added to the National Comprehensive Cancer Network adult glioma treatment guidelines as a Category 2A recommended treatment option.
DAWN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DAWN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 04, 2025 | $7.30 | $9.14 | +25.21% |
Aug 05, 2025 | $6.88 | $5.80 | -15.70% |
May 06, 2025 | $6.99 | $6.30 | -9.87% |
Feb 25, 2025 | $11.82 | $9.87 | -16.50% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Day One Biopharmaceuticals (DAWN) report earnings?
Day One Biopharmaceuticals (DAWN) is schdueled to report earning on Mar 09, 2026, After Close (Confirmed).
What is Day One Biopharmaceuticals (DAWN) earnings time?
Day One Biopharmaceuticals (DAWN) earnings time is at Mar 09, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DAWN EPS forecast?
DAWN EPS forecast for the fiscal quarter 2025 (Q4) is -0.21.